Epigenetic changes in newly diagnosed patients with inflammatory bowel disease may help determine which ones require aggressive therapy, new research suggests.
The study is part of a larger effort to identify biomarkers that predict susceptibility, progression and response to therapy of IBD, said Jack Satsangi, PhD, professor of gastroenterology at the University of Edinburgh, Scotland, who led the study. With numerous drugs for IBD on the horizon, with varying degrees of